Plain-English translation of NCT06735625 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying a protein called AHSP (alpha-hemoglobin stabilizing protein) to see if it could be a useful marker for sickle cell disease. This means they want to understand whether measuring this protein in your blood might help doctors better track how sickle cell disease is affecting your body. The study will compare AHSP levels in people who have sickle cell disease with those who do not.
Currently, doctors don't have simple, reliable ways to measure how severe sickle cell disease is or predict when complications might happen. Finding a blood marker like AHSP could give doctors a better tool to monitor patients and potentially improve treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would provide a single blood sample (about 4 milliliters, or less than a teaspoon) during a visit to the hospital. Researchers will measure the AHSP protein in your blood and compare your results with those of other participants. The blood sample will be stored in a secure, coded way to protect your privacy, and analyzed by the research team.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France
Sponsor
Centre Hospitalier de Saint-Denis
Collaborators
Inserm U955
Enrollment target
~100 participants
Started
March 2025
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
3 Years and older
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Stéphanie NGO, Coordinating Investigator
Centre Hospitalier de Saint-Denis
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.